MediWound (MDWD)
(Delayed Data from NSDQ)
$18.53 USD
-0.11 (-0.59%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $18.44 -0.09 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDWD 18.53 -0.11(-0.59%)
Will MDWD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDWD
Here's What Could Help MediWound (MDWD) Maintain Its Recent Price Strength
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MDWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates
Other News for MDWD
Vericel Corporation: Moving From Sell To Neutral
MediWound (MDWD) Garners Outperform Rating with Strategic Advancements | MDWD Stock News
Oppenheimer Sticks to Its Buy Rating for Mediwound (MDWD)
MediWound assumed with an Outperform at Oppenheimer
MediWound assumed with an Outperform at Oppenheimer